Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2022 May;78(5):891-893.
doi: 10.1007/s00228-022-03294-2. Epub 2022 Feb 18.

Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report

Stefania Cheli  1   2 , Valeria Cozzi  3 , Dario Cattaneo  3 , Lorenzo Norsa  4 , Costantino De Giacomo  5 , Emilio Clementi  6   7 , Chiara Moretti  5
Affiliations
Case Reports

Fast clearance of anti-TNFα agents unrelated to antidrug antibodies: a case report

Stefania Cheli et al. Eur J Clin Pharmacol. 2022 May.
No abstract available

PubMed Disclaimer

References

    1. Ben-Horin S, Kopylov U, Chowers Y (2014) Optimizing anti-TNF treatments in inflammatory bowel disease. Autoimmun Rev 13(1):24–30. https://doi.org/10.1016/j.autrev.2013.06.002 - DOI - PubMed
    1. Gisbert JP, Marín AC, McNicholl AG, Chaparro M (2015) Systematic review with meta-analysis: the efficacy of a second anti-TNF in patients with inflammatory bowel disease whose previous anti-TNF treatment has failed. Aliment Pharmacol Ther 41(7):613–623. https://doi.org/10.1111/apt.13083 - DOI - PubMed
    1. Papamichael K, Cheifetz AS (2019) Therapeutic drug monitoring in inflammatory bowel disease: for every patient and every drug? Curr Opin Gastroenterol 35(4):302–310. https://doi.org/10.1097/MOG.0000000000000536 - DOI - PubMed - PMC
    1. Regazzi M, Golay J, Molinaro M (2020) Monoclonal antibody monitoring: clinically relevant aspects, a systematic critical review. Ther Drug Monit 42(1):45–56. https://doi.org/10.1097/FTD.0000000000000681 - DOI - PubMed
    1. Jongsma MME, Winter DA, Huynh HQ, Norsa L, Hussey S, Kolho KL, Bronsky J, Assa A, Cohen S, Lev-Tzion R, Van Biervliet S, Rizopoulos D, de Meij TGJ, Shouval DS, Wine E, Wolters VM, Martinez-Vinson C, de Ridder L, Paediatric IBD Porto Group of ESPGHAN (2020) Infliximab in young paediatric IBD patients: it is all about the dosing. Eur J Pediatr 179(12):1935–1944. https://doi.org/10.1007/s00431-020-03750-0 - DOI - PubMed - PMC

LinkOut - more resources